Results 281 to 290 of about 911,530 (311)

Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial

Lancet, The, 2016
Sagar Lonial, Saad Z Usmani, Ajai Chari
exaly  

Refractory Laminitis

Veterinary Clinics of North America, 1973
openaire   +2 more sources

Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial

Lancet, The, 2014
Marcia S Brose, Barbara Jarząb, Rossella Elisei   +2 more
exaly  

Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study

Lancet, The, 2016
Wojciech Jurczak, Mats Jerkeman, Marek Trneny   +2 more
exaly  

Refractory Obesity

BMJ, 1963
openaire   +1 more source

Refractory sprue, coeliac disease, and enteropathy-associated T-cell lymphoma

Lancet, The, 2000
Eric Delabesse, Bana Jabri, Elizabeth Macintyre   +2 more
exaly  

Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study

Lancet, The, 2019
Paul G Richardson, S Vincent Rajkumar, Jesus San Miguel   +2 more
exaly  

Ciclosporin versus infliximab in patients with severe ulcerative colitis refractory to intravenous steroids: a parallel, open-label randomised controlled trial

Lancet, The, 2012
David Laharie, Matthieu Allez, Frank Zerbib   +2 more
exaly  

Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial

Lancet, The, 2014
Caroline Robert, Antoni Ribas, F Stephen Hodi   +2 more
exaly  

Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial

Lancet, The, 2018
Michael Wang, Simon A Rule, Pier Luigi Zinzani   +2 more
exaly